The Neurofibromatosis-associated Tumor Biobank

Neurofibromatosis-associated Tumor is very rare bone tumor. The investigator set up the biobank to ensure every patient has the chance to participate in future research

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Neurofibromatoses Bone Diseases Bone Neoplasms Congenital, Hereditary, and Neonatal Diseases and Abnormalities Genetic Diseases, Inborn Heredodegenerative Disorders, Nervous System Musculoskeletal Diseases Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Nerve Tissue Neoplastic Syndromes, Hereditary Nerve Sheath Neoplasms Nervous System Diseases Neurocutaneous Syndromes Neurodegenerative Diseases Neurofibroma

Sex eligibility

All sexes

Study type

Observational

About this study

Samples of blood and other stored material such as slides,frozen tissues or leftover diagnostic material.

Questionnaire information, including health history, growth and development, physical activity and family medical history information.

If patients have been diagnosed with a neurofibromatosis-associated tumor or another condition the investigator is interested in， the investigator will ask the patient to release medical record information relating to diagnosis and treatment of neurofibromatosis-associated tumor, other cancers, blood disorders, and similar conditions.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Proband Inclusion criteria: A diagnosis or suspected diagnosis of neurofibromatosis-associated tumor Family member inclusion criteria: Biological parents and full biological siblings of a case diagnosed with neurofibromatosis-associated tumor

Exclusion criteria

non-asian

Treatment and study plan

Primary outcomes

Detected NF-1 gene expression pattern in neurofibromatosis-asociated tumor

Time frame: 3 years

To examine the neurofibromatosis type 1(NF-1) gene expression of the patients with neurofibromatosis-associated tumor

Study contacts

Contact information is provided by the study sponsor or research team.

Kuisheng Liu, phD

CONTACT

[email protected]

+8601088324471

Sponsors and collaborators

Lead sponsor

Ren tingting

Other

Registry information

Official study title

Establishment of Neurofibromatosis-associated Tumours Biobank for Future Genomic-based Research Aiming at Improved Outcome Prediction

Important dates

Study start: 2018
Primary completion: 2023
Study completion: 2028
First posted: Dec 2, 2017
Registry last updated: Dec 2, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed